AbbVie   3Q Revenues: $5.9 billion (+18) 3Q Earnings: $1.2 billion  (earnings were $506 million 3Q14) YTD Revenues: $16.5 billion (+13%) YTD Earnings: $3.6 billion (+41%) Comments: Growth was driven by the continued strength of HUMIRA, up 12% to $3.6 billion in the quarter. IMBRUVICA sales were $304 million and VIEKIRA sales were $469 million in the quarter. Duodopa, Creon and Lupron sales were up 9%, 8%, and 2% respectively, while Kaletra sales declined 34% to $168 million, AndroG...